What changed for COPD
A plain English summary of what recently moved in the public data Voxsanity tracks for COPD. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 9 to 8 (-1)
- Trials recruiting worldwide 314 to 319 (+5)
- Late-stage (Phase 3) trials 17 to 18 (+1)
- Trials on record 3,766 to 3,853 (+87)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for COPD in July 2026. Voxsanity tracks 18 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 140 trials tracked for COPD that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03658538 · results posted 24 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03658538) involved people with COPD (a lung condition). A total of 59 people were assigned to the active treatment group and 61 to the control group (who did not receive the active treatment). Of those, 48 and 51 people respectively completed the trial. The trial was measuring changes in quality of life, breathlessness, general COPD health status, lung function, and how often participants needed healthcare due to COPD flare-ups — all tracked over a six-month follow-up period. The reported data shows the following changes...
-
NCT04765722 · results posted 16 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04765722) enrolled 30 people in total — 15 in a group receiving a medicine called mepolizumab and 15 in a group receiving a placebo (an inactive dummy treatment). All 15 people in the mepolizumab group completed the trial, while 14 of the 15 in the placebo group did so. The trial was measuring cough frequency — how many times per hour participants coughed, recorded by a monitoring device — as well as cough severity, to see how these figures changed over 14 weeks. The reported data shows the following numbers. For the main...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05349123 · results posted 6 June 2025
According to the results reported on ClinicalTrials.gov, this trial involved 99 people split into two groups — 48 in the intervention group and 51 in the control group. All 99 participants completed the study with no dropouts reported. The trial was measuring breathlessness, emotional wellbeing, and physical activity levels in people with a chronic respiratory (lung) condition, using two tools: a questionnaire called the Chronic Respiratory Disease Questionnaire (which asks people to rate their symptoms on a 1–7 scale, where higher scores mean less impact from symptoms), and a wearable activit...
-
NCT05305989 · results posted 2 May 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called belumosudil in people with chronic graft-versus-host disease (cGVHD) — a condition that can occur after a stem cell transplant when donor immune cells attack the recipient's body. A total of 23 people took part, split across three groups based on the dose they received: 13 people received 200 mg once a day, 9 people received 200 mg twice a day, and 1 person received 400 mg once a day. The trial measured several things, including how long any improvement in cGVHD signs lasted, changes in self-reporte...
-
NCT04456673 · results posted 17 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04456673) enrolled 935 people with chronic obstructive pulmonary disease (COPD) — 465 in the placebo group and 470 in the dupilumab 300 mg group. The trial ran for 52 weeks and was primarily measuring how often participants had moderate or severe COPD flare-ups (called exacerbations — episodes where symptoms worsen significantly, sometimes requiring hospital care or extra medicines). Secondary measurements included changes in lung airflow, and how participants rated their own breathing-related quality of life using a stand...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03655028 · results posted 17 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03655028) involved 93 people in total — 46 in a music-based walking group (called the RAS-music group, where participants walked in time with specially designed music) and 47 in a control group. All participants started the trial, but by the 12-week check-in, 10 people from the music group and 7 from the control group had dropped out, with similar small numbers leaving before the final 24-week check-in. The trial was measuring how far people could walk in six minutes, how active they were day-to-day, their quality of life,...
-
NCT02386722 · results posted 4 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02386722) enrolled 165 people with asthma or COPD (a lung condition causing breathing difficulties) — 84 in the intervention group and 81 in the control group. The trial ran for up to 182 days (roughly six months) and was measuring things like how long it took before a person had a flare-up (called an "exacerbation," meaning a sudden worsening that required medical attention), how many flare-ups occurred overall, how many were serious enough to need hospitalisation, and how consistently participants used their inhalers as...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03604692 · results posted 27 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03604692) enrolled 41 people in total across two phases. The first phase tested different doses of a drug called SNDX-6352 in small groups of patients to find a safe starting dose for a larger study — this is a standard first step when testing a new medicine. The second phase then enrolled 23 participants at the chosen dose to measure how often patients responded to the treatment. All participants had chronic graft versus host disease (cGVHD), a condition that can occur after a bone marrow or stem cell transplant. The rep...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04710576 · results posted 10 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04710576) looked at a medicine called axatilimab in people with chronic graft-versus-host disease (cGVHD) — a condition that can occur after a bone marrow or stem cell transplant, where the donated cells attack the recipient's body. A total of 241 people took part, split across three groups that each received a different dose or dosing schedule of axatilimab. The trial's main goal was to measure how many participants showed a meaningful improvement in their cGVHD symptoms within the first six treatment cycles, based on a r...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03959982 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03959982) enrolled 11 people in total — 8 in the HHHFA (heated humidified high-flow air) randomised group and 3 in the control group. The trial was measuring sleep quality, walking distance, and health-related quality of life in people with COPD (a lung condition), comparing those who received the HHHFA therapy against those who did not. Of the 11 who started, 7 completed the study — 4 from the HHHFA group and all 3 from the control group. The reported data shows the following changes over the 6-week study period. For sle...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01742338 · results posted 10 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT01742338) enrolled 89 people who had been hospitalised with a flare-up of COPD (chronic obstructive pulmonary disease). Participants were split into two groups: 47 received a lower dose of corticosteroids (a type of anti-inflammatory medicine) and 42 received a higher dose. The trial was measuring whether the dose of corticosteroids made a difference to a range of outcomes over 30 days, including death, needing a breathing machine, being re-admitted to hospital for COPD, or needing extra treatment. The reported data shows...
-
NCT05241288 · results posted 23 January 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 54 people who used a smart inhaler called the ProAir® Digihaler® (which contains a reliever medicine called albuterol) over three months. The inhaler has built-in sensors that automatically record how a person breathes in when they use it. The trial was measuring how much a person's peak inspiratory flow — the fastest speed at which they inhale — varied from use to use over time, and also looked at things like how much air people breathed in with each puff and whether people's own memory of how often they used the inh...
-
NCT03085485 · results posted 21 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 people in total — 30 received ivacaftor and 10 received a placebo (an inactive look-alike treatment). Of those, 28 in the ivacaftor group and all 10 in the placebo group completed the study. The trial was primarily measuring a number of safety-related things in people taking ivacaftor, and also looked at two secondary measures related to how a protein called CFTR was functioning in the body — one measured in the lungs (mucociliary clearance, which is how well the lungs clear mucus) and one measured through a sweat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04072887 · results posted 28 April 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04072887) enrolled 974 people in total across six groups. Participants received one of five different doses of a drug called QBW251 (25 mg, 75 mg, 150 mg, 300 mg, or 450 mg) or a placebo (a dummy treatment with no active ingredient). The trial was measuring changes in lung function and respiratory symptoms in people with a chronic lung condition, over a period of up to 24 weeks. The main thing the trial was set up to measure was a lung function test called FEV1 — essentially how much air a person can forcibly breathe out i...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02013427 · results posted 3 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02013427) involved 82 people across three groups: 25 in an observational group (no treatment, just monitored), 5 who received a combination of naproxen and omeprazole (a pain-relief medicine and a stomach-protecting medicine), and 52 who received a placebo (a dummy treatment with no active ingredients). Not everyone finished the study — 20, 4, and 43 people completed it in each group respectively. The trial was measuring changes in self-reported pain levels over 6 weeks, using a scale from 0 (no pain) to 10 (worst imaginab...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03546907 · results posted 22 November 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03546907) enrolled 343 people with chronic obstructive pulmonary disease (COPD) — 171 received a placebo (a dummy treatment with no active ingredient) and 172 received the investigational medicine SAR440340. The trial was primarily measuring how often participants experienced moderate or severe flare-ups of their COPD (called exacerbations) over the course of the study. Secondary measurements included changes in lung function, specifically how much air a person could forcefully breathe out in one second (a standard lung fu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02867761 · results posted 30 August 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 535 people in total — 261 received a combination inhaler containing two medicines called indacaterol and glycopyrrolate, and 274 received a placebo (an inactive, dummy treatment). The trial ran for 12 weeks and was designed to measure whether people's breathing-related quality of life improved, using several standardised questionnaires. These questionnaires ask people to rate how much their breathing symptoms affect their day-to-day life, with lower scores meaning fewer symptoms. The trial also tracked "treatment fail...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03112603 · results posted 15 April 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 329 people in total — 165 received ruxolitinib and 164 received what the trial called "best available therapy" (the best standard treatment the doctor could offer). A further 70 people who had been in the standard-treatment group later crossed over to receive ruxolitinib in a separate phase of the trial. The trial was measuring responses in people with a condition called chronic graft-versus-host disease that had stopped responding to steroids — a complication that can occur after a bone marrow or stem cell transplant...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04011475 · results posted 11 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04011475) looked at people with a chronic lung condition (likely COPD) who were taking one of three different inhaled medication combinations. A total of 1,617 people were enrolled across three groups: 239 people took a combination called tiotropium and olodaterol (Group A), 937 people took a different two-medicine combination from the same drug classes (Group B), and 441 people took a single medicine from one of those classes (Group C). The trial was observational — meaning researchers watched what happened to people alre...
-
NCT04249310 · results posted 30 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT04249310) looked at two groups of people with chronic obstructive pulmonary disease (COPD) — a lung condition — who were taking one of two inhaled breathing medicines: a combination medicine called Tiotropium/Olodaterol (Spiolto®), or Tiotropium alone (Spiriva®). In total, 1,436 people were in the Spiolto® group and 5,352 in the Spiriva® group at the start. To make a fairer comparison between the two groups, the researchers used a statistical matching process that paired similar patients together, resulting in 1,412 matche...
-
NCT02261727 · results posted 12 August 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,670 people across three groups: one group received low-dose theophylline (a type of medication), one received a combination of theophylline and prednisone (a steroid), and one received a placebo (a dummy treatment with no active ingredient). All participants had COPD (a lung condition) and were followed for 48 weeks. The trial was primarily measuring how often participants had COPD flare-ups (called exacerbations) during that time. Not everyone finished the study — around 411–423 people per group completed it out of...
-
NCT04107493 · results posted 26 May 2021
According to the results reported on ClinicalTrials.gov, this trial involved 33 people in total, split into two groups of 16 and 17. It used a "crossover" design, meaning each participant tried both devices — a standard portable oxygen cylinder and a device called the Mobi™ Portable Oxygen Concentrator — in a different order, with a rest period in between. The trial was measuring blood oxygen levels (the amount of oxygen being carried in the blood, recorded as a percentage) while participants completed a six-minute walking test using each device. The reported data shows that during the six-mi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02959944 · results posted 4 May 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 193 people — 95 in the ibrutinib plus prednisone group and 98 in the placebo plus prednisone group. All participants had chronic graft-versus-host disease (cGVHD), a condition that can occur after a stem cell or bone marrow transplant where the donor cells attack the recipient's body. The trial was measuring whether adding ibrutinib (a tablet medicine) to the steroid prednisone made a difference compared to adding a dummy pill (placebo) to prednisone. The main thing being measured was the proportion of participants wh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04155047 · results posted 8 April 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT04155047) involved 22 participants in total — 11 in each group. It used a "crossover" design, meaning participants tried both treatments at different times: one group received a Glycopyrrolate Inhalation Solution (GIS) first and then a placebo (an inactive, dummy inhaler), while the other group received the placebo first and then GIS. The trial was measuring changes in something called **Residual Volume (RV)** — this is the amount of air left in the lungs after a person breathes out as fully as they can. A higher residual...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03137992 · results posted 5 April 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03137992) enrolled 374 participants in total across six groups. Each group received three different inhaled treatments in a different order — a test version of tiotropium bromide powder (made by Lupin), the brand-name version called Spiriva®, and a placebo (an inactive dummy inhaler) — with rest periods in between. The trial was measuring how much air participants could breathe out in one second over a 24-hour period after a single dose, a measurement known as FEV1 (forced expiratory volume in one second). The goal was to...
-
NCT03611777 · results posted 17 February 2021
According to the results reported on ClinicalTrials.gov, this study enrolled 901 people with COPD (chronic obstructive pulmonary disease, a lung condition that makes breathing difficult). Of these, 432 were taking inhaled corticosteroids (a type of inhaled preventer medicine, often called ICS) at the time of their study visit, and 469 were not. The study was observational — meaning researchers looked back at medical records rather than testing a new treatment — and it focused on counting how often participants had experienced serious flare-ups (called "exacerbations") of their COPD in the one...
-
NCT02465567 · results posted 2 February 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 8,588 people across four treatment groups, all of whom had COPD (a lung condition). The four groups each received a different inhaled combination of medicines delivered by a pressurised inhaler: two groups received a triple combination called BGF MDI (at different doses), one group received a double combination called GFF MDI, and one group received a different double combination called BFF MDI. The trial's main focus was on measuring the rate of moderate or severe COPD flare-ups (called exacerbations — episodes where...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03159091 · results posted 11 December 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03159091) enrolled 238 people with a chronic cough related to chronic obstructive pulmonary disease (COPD) — a long-term lung condition that makes it harder to breathe. Of these, 121 were assigned to receive a medicine called Rengalin and 117 received a placebo (a dummy treatment with no active ingredient). The trial ran for four weeks and was mainly measuring whether people's cough severity improved, using a scoring tool called the Cough Severity Scale (CSS), where 0 means no cough at all and 5 means a constant, exhaustin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02649218 · results posted 14 August 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02649218) enrolled 226 adults with a condition called Chronic Spontaneous Urticaria (CSU) — a form of ongoing hives that appears without a clear trigger. All participants received a treatment called ligelizumab over approximately one year, as a follow-on from an earlier study. By the end of the trial, 201 participants had completed it, while 25 did not finish. The trial was measuring two main things: how many participants experienced unwanted health events (called adverse events) during treatment, and how many participants...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03165045 · results posted 1 April 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,351 people who were using a combination inhaler called Spiolto® Respimat®. There was only one group — everyone received the same inhaler. The trial was measuring several things over roughly six weeks, including a "therapeutic success" rate, changes in a health questionnaire score (called the CCQ, which asks 10 questions about symptoms, daily functioning, and mental state), how doctors rated patients' general condition, and how satisfied patients were with the inhaler. The reported data shows that 756 out of the 1,1...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 140 reported results for COPD
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research money is currently being directed toward COPD, and that investment has been growing year on year. This suggests that COPD is considered a significant research priority at an international level, with scientists and institutions actively pursuing a deeper understanding of the condition. For patients, rising and substantial fundin...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.